Article
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.
RMD Open
Document Type
Response or Comment
Publication Date
9-7-2018
Disciplines
Clinical Institute
Orthopedics & Sports Medicine
Department
Rheumatology
Department
Orthopedics
Citation Information
Philip Mease, A Kavanaugh and A Reimold. "Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial." RMD Open (2018) Available at: http://works.bepress.com/philip-mease/386/
This corrects the article "Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial" DOI: 10.1136/rmdopen-2018-000723